CLDX

CDX-0159

KIT/Mast Cell Diseases

Phase 1

Exp Date

Q1 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: CDX-0159 for KIT/Mast Cell Diseases - Phase 1 

  • ClinicalTrial.gov (NCT04548869): A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Urticaria or Symptomatic Dermographism


WHAT IS THE NEXT CATALYST EVENT?

  • Topline Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • 2H 2021


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells.  In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease.

Updated by JM 

CLDX, CELLDEX, CDX-0159, KIT/Mast Cell Diseases

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon